2022 Q1 lipid-lowering drug sales TOP10, it is still unmatched

Hyperlipidemia is a common disease caused by abnormal lipid metabolism in the human bod.

Driven by both stock demand and incremental demand, China's hypolipidemic drug market continues to gro.

TOP10 hypolipidemic drugs

However, since the blood lipid lowering drugs, especially the four major statins (atorvastatin, rosuvastatin, pitavastatin and simvastatin) have been reviewed and the implementation of the national centralized procurement, the domestic blood lipid regulator market has opene.

Despite the sharp drop in drug prices, the dominance of statins has not been shake.

Among the top 10 best-selling lipid-lowering drugs, statins occupy 6 seats, namely atorvastatin (1), rosuvastatin (2), amlodipine atorvastatin (4), pravastatin (5), Pitavastatin calcium (9), fluvastatin (10.

The strong are still the sam.

Cholesterol absorption inhibitor ezetimibe (3) has performed well in recent years, ranking third from the tenth place in 2018, and far ahead of the latter products, with a market share of 175%, which is vaguely catching up with Switzerland The trend of suvastati.

The niacin derivative axilimus (6) is a second-line lipid-lowering drug, often used as an alternative treatment when other lipid-lowering drugs cannot be use.

Iloyoumab (8) is a PCSK9 inhibitor and a new type of lipid-lowering drug, which was only launched in China in 2019. The lipid-lowering effect of ilovolumab is very good, and single-drug therapy can reduce LDL-C (low-density lipoprotein cholesterol) by an average of 60%, which is more than powerful lipid-lowering drugs such as atorvastatin calciu.

This compound statin product may enter the centralized collection

In addition to the first few batches of lipid-lowering drugs that have entered the list of centralized procurement, the seventh batch of centralized procurement will include Yizhe Maibu Tablets, which will be won by Hunan Fangsheng, Beijing Fuyuan, Sandoz and Chongqing Shenghuaxi respectivel.

At present, in the main varieties of hypolipidemic drugs, except for statins, the consistency evaluation progress of most varieties is still far away or even has not been carried ou.

Some people predict that if the eighth batch of national procurement focuses on chemical drugs, amlodipine and atorvastatin calcium tablets are expected to enter the national procurement, and may become one of the varieties with fierce biddin.